HYHing-Yuen Yeung

Hing-Yuen Yeung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hing-Yuen Yeung has a total of 240 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    hadge: a comprehensive pipeline for donor deconvolution in single cell

    by Fabiola Curion, Xichen Wu, Lukas Heumos, Mariana Gonzales, Lennard Halle, Melissa Grant-Peters, Charlotte Rich-Griffin, Hing-Yuen Yeung, Calliope A. Dendrou, Herbert B. Schiller, et al.

    Single cell multiplexing techniques (cell hashing and genetic multiplexing) allow to combine multiple samples, thereby optimizing sample processing and reducing batch effects. Cell hashing conjugates antibody-tags or chemical-oligonucleotides to cell membranes, while genetic multiplexing allows to mix genetically diverse samples and relies on aggregation of RNA reads at known genomic coordinates. We developed hadge ( ha shing d econvolution combined with ge notype information), a Nextflow pipeline that combines 12 methods to perform both hashing- and genotype-based deconvolution. We propose a joint deconvolution strategy combining the best performing methods and we demonstrate how this approach leads to recovery of previously discarded cells in a nuclei hashing of fresh-frozen brain tissue.


  • Open Access

    Biochemical and metabolic maladaption defines pathological niches in progressive multiple sclerosis

    by Melissa Grant-Peters, Charlotte Rich-Griffin, Hing-Yuen Yeung, Tom Thomas, Simon Davis, Mohammad Azizian, Joseph Fisher, Roman Fischer, Gianfelice Cinque, Calliope A. Dendrou

    Progressive multiple sclerosis (MS) is driven by demyelination, neuroaxonal loss, and mitochondrial damage occurring behind a closed blood-brain barrier (BBB). 1,2 Patients with progressive MS typically fail to respond to available immunomodulatory drugs that reduce relapses in early disease. 2 This indicates a dire need to identify non-canonical therapeutic avenues to limit neurodegeneration and promote protection and repair. 3 Here, we have employed high-resolution multiomic profiling to characterise the biochemical and metabolic adaptations underpinning MS pathology, as these have been incompletely described but critically, may be amenable to BBB-permeable drug targeting. Using synchrotron radiation (SR)- and focal plane array (FPA)-based Fourier transform infrared microspectroscopy (μFTIR), we spatially mapped the biochemical features present in human progressive MS and control post-mortem brain and rare spinal cord tissue. By employing single-nuclear RNA sequencing (snRNA-seq), 10x Genomics Visium spatial transcriptomics and spatial proteomics to resolve their cellular context, we found that these biochemical features provide a uniquely and highly disease-specific barcode for distinct pathological niches within the tissue. Characterisation of the metabolic processes underpinning these niches revealed an associated re-organisation of the astrocytic landscape in the grey and white matter, with implications for the treatment of progressive MS.


  • Open Access

    A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

    by David J Ahern, Zhichao Ai, Mark Ainsworth, Chris Allan, Alice Allcock, Azim Ansari, Carolina V Arancibia-Carcamo, Dominik Aschenbrenner, Moustafa Attar, J. Kenneth Baillie, et al.

    Summary: Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete understanding of potentially druggable immune mediators of disease. To advance this, we present a comprehensive multi-omic blood atlas in patients with varying COVID-19 severity and compare with influenza, sepsis and healthy volunteers. We identify immune signatures and correlates of host response. Hallmarks of disease severity revealed cells, their inflammatory mediators and networks as potential therapeutic targets, including progenitor cells and specific myeloid and lymphocyte subsets, features of the immune repertoire, acute phase response, metabolism and coagulation. Persisting immune activation involving AP-1/p38MAPK was a specific feature of COVID-19. The plasma proteome enabled sub-phenotyping into patient clusters, predictive of severity and outcome. Tensor and matrix decomposition of the overall dataset revealed feature groupings linked with disease severity and specificity. Our systems-based integrative approach and blood atlas will inform future drug development, clinical trial design and personalised medicine approaches for COVID-19.


  • Pregnancy Immunogenetics and Genomics: Implications for Pregnancy-Related Complications and Autoimmune Disease

    by Hing-Yuen Yeung, Calliope A. Dendrou

    Pregnancy presents a singular physiological scenario during which the maternal immune system must accommodate the semiallogeneic fetus. Fluctuations between pro- and anti-inflammatory states are required throughout gestation to facilitate uterine tissue remodeling, fetal growth and development, and finally birth. Tolerance for the fetus must be established and maintained without fundamentally compromising the maternal immune system function, so that both the mother and fetus are protected from foreign insults. Here, we review our current understanding of how genetic variation at both maternal and fetal loci affects implantation and placenta formation, thereby determining the likelihood of a successful pregnancy outcome or the development of pregnancy-related complications. We also consider the impact of pregnancy on both the maternal and fetal systemic immune systems and the related implications for modulating ongoing autoimmune diseases and triggering their development.


  • PS-127-Analysis of liver infiltrating lymphocytes in primary sclerosing cholangitis by surface antigen and single cell RNAseq

    by Kate Lynch, Fabiola Curion, Hing-Yuen Yeung, Eve Fryer, Andrew Slater, Helen Ferry, Moustafa Attar, Hubert Slawinski, Roger W.G. Chapman, Rory Bowden, et al.


  • Automated real-time detection of drug-resistant Mycobacterium tuberculosis on a lab-on-a-disc by Recombinase Polymerase Amplification

    by I.L.G. Law, J.F.C. Loo, H.C. Kwok, H.Y. Yeung, C.C.H. Leung, M. Hui, S.Y. Wu, H.S. Chan, Y.W. Kwan, H.P. Ho, et al.


  • Photodynamic Therapy

    by Wing-Ping Fong, Hing-Yuen Yeung, Pui-Chi Lo, Dennis K. P. Ng


  • Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model

    by Hing-Yuen Yeung, Pui-Chi Lo, Dennis K.P. Ng, Wing-Ping Fong

    In recent decades, accumulating evidence from both animal and clinical studies has suggested that a sufficiently activated immune system may strongly augment various types of cancer treatment, including photodynamic therapy (PDT). Through the generation of reactive oxygen species, PDT eradicates tumors by triggering localized tumor damage and inducing anti-tumor immunity. As the major component of anti-tumor immunity, the involvement of a cell-mediated immune response in PDT has been well investigated in the past decade, whereas the role of humoral immunity has remained relatively unexplored. In the present investigation, using the photosensitizer BAM-SiPc and the CT26 tumor-bearing BALB/c mouse model, it was demonstrated that both cell-mediated and humoral adaptive immune components could be involved in PDT. With a vascular PDT (VPDT) regimen, BAM-SiPc could eradicate the tumors of ∼ 70% of tumor-bearing mice and trigger an anti-tumor immune response that could last for more than 1 year. An elevation of Th2 cytokines was detected ex vivo after VPDT, indicating the potential involvement of a humoral response. An analysis of serum from the VPDT-cured mice also revealed elevated levels of tumor-specific antibodies. Moreover, this serum could effectively hinder tumor growth and protect the mice against further re-challenge in a T-cell-dependent manner. Taken together, these results show that the humoral components induced after BAM-SiPc-VPDT could assist the development of anti-tumor immunity.